Subsense Inc.

We’re excited to welcome Gary Lo, CPA as Subsense’s new CFO. Gary brings 30+ years of experience helping deep-tech and life sciences companies scale — from early growth to commercialization. He’s previously led finance and fundraising at Beyeonics Vision and Cellares, building the foundations needed for global growth. At Subsense, Gary will help shape our financial strategy as we move into the next phase of building a new category of non-surgical brain-computer interfaces. Welcome to the team, Gary!

We’re proud to welcome two world-class leaders to Subsense’s Scientific and Product Advisory Boards. John-Clark Levin, Research Lead at Kurzweil Technologies Inc., joins Subsense as a Product Advisor. He brings a rare combination of AI systems thinking, policy expertise, and life sciences insight, advising governments, NGOs, and Fortune 500 companies on emerging technologies. His background spans AI research at Harvard and Cambridge, alongside senior advisory roles at Greenmantle and the Yorktown Institute. We’re also honored to welcome Naomi Halas as a Scientific Advisor. She is a University Professor and Stanley C. Moore Professor of Electrical and Computer Engineering at Rice University, one of the world’s leading pioneers of plasmonics and nanophotonics. Professor Halas has fundamentally shaped how light–matter interactions are applied across biomedicine and sensing. She is a member of both the National Academy of Engineering and the National Academy of Sciences, and the recipient of the 2025 Franklin Medal in Chemistry. Their combined perspectives — spanning AI, advanced nanotechnology, and real-world translation — are an extraordinary addition to Subsense. We’re incredibly excited to have them helping guide us as we build a new category of non-surgical brain-computer interfaces.

We’re excited to welcome Andrew Ostarello as Chief of Staff, Vandana V. as R&D Project Manager, and Ranya Belmaachi as Product Manager at Subsense. Andrew most recently founded and led Only Choices, demonstrating the ability to set direction at the executive leadership level, coordinate teams across the organization, and lead critical initiatives through to completion. Vandana joins from NASA Ames Research Center, bringing experience coordinating cross-functional teams, managing timelines, and working with external partners on R&D programs in regulated research environments across biology and data systems. Ranya joins us from OpenBCI, serving as a Technical Product Manager (Product + AI/ML) and owning the full product lifecycle for next-generation neurotechnology platforms from early discovery through launch. Together, they strengthen Subsense’s ability to move faster, make better product decisions, and translate advanced neuroscience into systems that work reliably at scale for our non-surgical, brain-computer interface platform. 

I’ll be attending #BiotechShowcase during #JPM2026 in San Francisco, January 12-14. I’ll be presenting and sharing updates on Subsense Inc.’s progress and the development of our non-surgical, nanoparticle-based brain-computer interface platform. If you’d like to connect with me while in SF, please get in touch or search for Subsense on the partneringONE platform. #Neurotechnology #BCI #Biotech #JPM26 Informa Connect

Subsense is pleased to announce $10 million in new capital from Golden Falcon Capital to accelerate development of our non-surgical brain-computer interface platform. Co-founder and CEO, Tetiana Aleksandrova, says, “We are developing a new kind of neural interface, which integrates seamlessly with the human body. This bio-integrated approach is fundamentally enhancing safety and expanding accessibility.” This financing follows early technical progress across materials development, in vitro nanoparticle stimulation and signal reading, and supports continued investment in nanoparticle sensing, in vivo biosafety programs, next-generation nanoparticle design, and hardware miniaturization. Read the Axios story from Katherine Davis here, and you can see our press release in the comments. https://lnkd.in/gJkW7AeJ  #Neurotechnology #BrainComputerInterface #BCI #Funding #Neurotech

We’re excited to welcome Rose Monaghan, MS to Subsense as our new Senior Director, R&D Systems. Rose brings deep expertise across medical device R&D, systems engineering, and product commercialization, with a track record spanning Class II/III devices, advanced healthcare systems, and integrated hardware-software platforms. She has led multidisciplinary teams from early concept through FDA submission and launch, and holds more than 20 issued and pending patents. Prior to Subsense, Rose helped launch Frond Medical, a company developing precision digital guidance technologies for cardiology and pulmonology conditions, and held senior R&D leadership roles at Boston Scientific and PerkinElmer Medical Imaging, advancing next-generation imaging and physiology platform devices for diagnostics and therapeutics. At Subsense, Rose will lead our systems development as we continue building a robust, scalable foundation for our non-surgical, nanoparticle-based brain-computer interface platform, and helping align neuroengineering with clinical, regulatory, and long-term product strategy. Welcome to the team, Rose! #Neurotechnology #BrainComputerInterface #BCI #Neurotech

We’re still searching for our Head of Product at Subsense — and we won’t stop until we find the one. If you’re looking for a “normal” job — keep scrolling. Nothing is normal here. We don’t build boring products. We build technologies that change the very foundation of how the brain interacts with machines. And we need someone who’s not afraid to take on a product that lives at the edge of science fiction → science reality. You will: 🚀 Turn neuroscience and nanotech into products that textbooks will be written about 🚀 Work with scientists, engineers, investors, and clinicians like the conductor of a grand orchestra 🚀 Build not “just another app,” but the interface between the brain and the world This is a rare chance: to be the one defining what the world’s first non-surgical bidirectional brain-computer interface will look like. Yes, it sounds bold. Because we’re not playing startup. We’re building the future. 🌟 If you’ve got ambition, drive, and serious product leadership experience — message me. Like. Share. Repost 🧠💪🚀 #BCI #HeadOfProduct #Neurotech #Future

The future of brain-computer interfaces may not be implanted, but flow through the bloodstream. At Subsense, we’re developing a non-surgical, nanoparticle-based interface that merges neurobiology and AI to decode intent without invasive procedures. This approach could radically expand who benefits from neural technologies, making restoration and augmentation accessible far beyond clinical environments. Subsense CEO and co-founder Tetiana Aleksandrova will be sharing this vision on Nov. 5 at the Neurotech Leaders Forum, joining JoJo (Jo Ann) Platt from Neurotech Reports, Oliver Armitage from Axoft, and Andreas Forsland from Cognixion for a discussion on how #AI and #BCI are converging to transform human communication and control. If you’ll be there, please let us know if you’d like to meet and learn more about Subsense. Agenda: https://lnkd.in/eb3BnPm

I’m honored to join fellow founders Maria Soloveychik from SyntheX, Karen Baert from Ammobia, Tara Ghazi, PhD from MALCOVA, and Anna Chukaeva from Carta Healthcare and Intercellular for Frontiers of Deep Tech: Journeys of Female Founders, hosted by Draper University and Female Founders Edge on November 4. Each of us will share the unfiltered reality of building companies where science meets scale, from early experiments to leadership under pressure. For me, leading Subsense Inc. has been a lesson in persistence, precision, and community. I’m looking forward to exchanging stories with others who are navigating the same frontier.

Every advance in brain-computer interfaces has come with a tradeoff: precision in exchange for surgery. At Subsense, we’re removing that tradeoff. Our team is developing a new kind of BCI that works through a nasal spray. Tiny engineered nanoparticles travel into the brain, where they act as miniature antennas to read and stimulate neural activity. The result could match the capabilities of implanted electrodes, without the risks and costs of invasive procedures. The implications extend from treating neurological disease to unlocking new forms of cognition for healthy individuals. Led by CEO Tetiana Aleksandrova, our Palo Alto team is preparing in vivo studies to demonstrate the potential of nanoparticle BCIs. Non-invasive neural interfaces are not a distant dream. They are the next step toward making brain technology safe and scalable for everyone. Read the interview with Tetiana and Scott Meek, Ph.D. with Neurofounders: https://lnkd.in/eV8w8Bji